Physician profile
Kelcey Mar
NPI 1831802875
$995.34
in general payments reported to CMS, 2019-2025
15 companies · $14.82 in 2025
The $14.82 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $244 · 2024: $736 · 2025: $14.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $246.15 | 2023-2024 | Tezspire, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $177.61 | 2024 | Hyqvia, Cuvitru, Gattex |
| Glaxosmithkline, LLC. | $136.45 | 2023-2024 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $97.56 | 2024 | |
| Kaleo, INC. | $76.05 | 2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $44.26 | 2024 | Dupixent |
| Aerin Medical INC. | $35.20 | 2024 | |
| Amgen INC. | $34.92 | 2024 | Tezspire |
| Octapharma USA, INC. | $30.66 | 2024-2025 | Cutaquig, Panzyga |
| Amarin Pharma, INC. | $24.52 | 2023 | |
| Blueprint Medicines Corporation | $22.09 | 2024 | Ayvakit |
| Genzyme Corporation | $20.97 | 2024 | |
| Exact Sciences Corporation | $19.80 | 2024 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $15.79 | 2024 | Ryaltris |
| Csl Behring | $13.31 | 2024 | Haegarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelcey Mar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.